

Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing. The backer was Deerfield Management.
Source: Press Release
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.
Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing. The backer was Deerfield Management.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination